Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $1.6 million.

  • Fortress Biotech's Other Non-Current Liabilities fell 781.52% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 781.52%. This contributed to the annual value of $1.8 million for FY2024, which is 723.72% down from last year.
  • Per Fortress Biotech's latest filing, its Other Non-Current Liabilities stood at $1.6 million for Q3 2025, which was down 781.52% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Other Non-Current Liabilities peaked at $4.4 million during Q3 2021, and registered a low of $1.6 million during Q3 2025.
  • For the 5-year period, Fortress Biotech's Other Non-Current Liabilities averaged around $2.1 million, with its median value being $1.8 million (2022).
  • Per our database at Business Quant, Fortress Biotech's Other Non-Current Liabilities plummeted by 7367.55% in 2021 and then surged by 436.15% in 2022.
  • Over the past 5 years, Fortress Biotech's Other Non-Current Liabilities (Quarter) stood at $2.0 million in 2021, then decreased by 9.15% to $1.8 million in 2022, then grew by 2.49% to $1.9 million in 2023, then decreased by 7.24% to $1.8 million in 2024, then fell by 7.97% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.7 million for Q2 2025, and $1.7 million during Q1 2025.